{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,24]],"date-time":"2025-08-24T23:07:21Z","timestamp":1756076841992,"version":"3.40.5"},"reference-count":36,"publisher":"VM Media Group sp. z o.o","issue":"4","license":[{"start":{"date-parts":[[2015,7,1]],"date-time":"2015-07-01T00:00:00Z","timestamp":1435708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neurologia i Neurochirurgia Polska"],"published-print":{"date-parts":[[2015,7]]},"DOI":"10.1016\/j.pjnns.2015.06.003","type":"journal-article","created":{"date-parts":[[2015,6,18]],"date-time":"2015-06-18T07:58:51Z","timestamp":1434614331000},"page":"278-289","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Reversal of antithrombotic treatment in intracranial hemorrhage \u2013 A review of current strategies and guidelines"],"prefix":"10.5603","volume":"49","author":[{"given":"Tomasz","family":"Grzegorski","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natalia","family":"Andrzejewska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0807-8796","authenticated-orcid":false,"given":"Rados\u0142aw","family":"Ka\u017amierski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3595","reference":[{"issue":"1 Suppl. 1","key":"10.1016\/j.pjnns.2015.06.003_bib0185","first-page":"S1","article-title":"Post\u0119powanie w udarze, m\u00f3zgu., Wytyczne Grupy Ekspert\u00f3w Sekcji Chor\u00f3b Naczyniowych Polskiego Towarzystwa, Neurologicznego","volume":"46","year":"2012","journal-title":"Neurol Neurochir Pol"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0190","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/ijs.12309","article-title":"European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage","volume":"9","author":"Steiner","year":"2014","journal-title":"Int J Stroke"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0195","doi-asserted-by":"crossref","first-page":"2108","DOI":"10.1161\/STR.0b013e3181ec611b","article-title":"Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"41","author":"Morgenstern","year":"2010","journal-title":"Stroke"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0200","series-title":"Providing acute care","first-page":"99","article-title":"Anticoagulation strategies","author":"Wijdicks","year":"2014"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0205","series-title":"Neurocritical care","first-page":"13","article-title":"Reversal of anticoagulation after cerebral hemorrhage","author":"Wijdicks","year":"2012"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0210","series-title":"Decision making in neurocritical care","first-page":"52","article-title":"Antiplatelet- and anticoagulation-associated intracranial hemorrhage","author":"Rincon","year":"2009"},{"year":"2013","series-title":"Acenocumarol WZF tabl 4mg. Summary of product characteristics (SPC), Polish version","key":"10.1016\/j.pjnns.2015.06.003_bib0215"},{"year":"2014","series-title":"Sinthrome tabl 1mg. Summary of product characteristics (SPC), British version","key":"10.1016\/j.pjnns.2015.06.003_bib0220"},{"year":"2012","series-title":"Warfin tabl 3 and 5mg. Summary of product characteristics (SPC), Polish version","key":"10.1016\/j.pjnns.2015.06.003_bib0225"},{"year":"2014","series-title":"Warfarin 5mg. Summary of product characteristics (SPC), British version","key":"10.1016\/j.pjnns.2015.06.003_bib0230"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0235","unstructured":"Xarelto tabl 10mg, 15mg and 20mg. Summary of product characteristics (SPC), Polish Version (2008) as amended later (2012). http:\/\/leki.urpl.gov.pl\/files\/Xarelto_tablpowl_10mg.pdf"},{"year":"2013","series-title":"Xarelto tabl 10mg, 15mg and 20mg. Summary of product characteristics (SPC), EMA version","key":"10.1016\/j.pjnns.2015.06.003_bib0240"},{"year":"2008","series-title":"Dabigatran tabl. 110 and 150mg. Summary of product characteristics (SPC), Polish version","key":"10.1016\/j.pjnns.2015.06.003_bib0245"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0250","unstructured":"Dabigatran tabl. 110 and 150mg. Summary of product characteristics (SPC), EMA version. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000829\/WC500041059.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0255","unstructured":"Apixaban (Apiksaban) tabl. 2,5mg. Summary of product characteristics (SPC), Polish version (year not specified in SPC). http:\/\/leki.urpl.gov.pl\/files\/16_Eliquis.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0260","unstructured":"Apixaban (Apiksaban) tabl. 2,5 and 5mg. Summary of product characteristics (SPC), EMA version (2011). http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/002148\/WC500107728.pdf [in press]."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0265","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00392-013-0560-7","article-title":"Recommendations for the emergency management of complications associated with new direct oral anticoagulants (DOAC) apixaban, dabigatran, and rivaroxaban","volume":"102","author":"Steiner","year":"2013","journal-title":"Clin Res Cardiol"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0270","unstructured":"Clexane 100mg\/ml, solution for injection. Summary of product characteristics (SPC), Polish version (2008) as amended. http:\/\/www.urpl.gov.pl\/system\/drugs\/pn\/charakterystyka\/2011-09-06_chpl_clexane_100_mg_ml.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0275","unstructured":"Clexane Forte Syringes Injection. The Summary of Product Characteristics (SPC), British version 2014. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1416549019162.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0280","unstructured":"Fraxiparine (Nadroparinum calcicum) from 2\u00a0850 j.m., to 9 500 j.m. AXa Summary of product characteristics (SPC), Polish version (2008) as amended. http:\/\/leki.urpl.gov.pl\/files\/Fraxiparine.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0285","unstructured":"Fragmin (dalteparinum natricum) from 2\u00a0500 j.m. to 18\u00a0000 j.m. anty-Xa, Summary of product characteristics (SPC), Polish version (2012) as amended. http:\/\/www.urpl.gov.pl\/system\/article_attachments\/attachments\/3634\/original\/FRAGMIN_ChPL_27.09.2012.pdf?1349444201."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0290","unstructured":"Fragmin 18,000IU\/0.72ml solution for injection. The summary of product characteristics (SPC), British version 2013. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1406267581180.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0295","unstructured":"Heparinum WZF (heparinum natricum), 5000j.m.\/mL, (solution for injection). Summary of product characteristics (SPC), Polish version (1968). Charakterystyka Produktu Leczniczego amended (2008). Ministerstwo Zdrowia, Departament Polityki Lekowej i Farmacji. http:\/\/leki-informacje.pl\/jamnik\/img\/galeriaplikow\/3\/heparinumWZF_spc.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0300","unstructured":"Heparin Sodium BP 5000IU\/L in 0.9% w\/v sodium chloride IV infusion. The summary of product characteristics. British version 2014. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1415946068743.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0305","unstructured":"Actylise 50mg. Summary of product characteristics (SPC), Polish Version (1991) as amended (2014). http:\/\/www.urpl.gov.pl\/system\/drugs\/pn\/charakterystyka\/2014-05-21_smpc_actilyse_50_mg__16.05.2014.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0310","unstructured":"Actilyse 10, 20, 50mg \u2013 powder and solvent for solution for injection and infusion. The summary of product characteristics. British version 2013. http:\/\/www.mhra.gov.uk\/home\/groups\/spcpil\/documents\/spcpil\/con1421388295918.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0315","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1161\/STR.0b013e318284056a","article-title":"Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association\/American Stroke Association","volume":"44","author":"Jauch","year":"2013","journal-title":"Stroke"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0320","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1007\/s12028-012-9681-5","article-title":"Treatment of intracerebral hemorrhage with tranexamic acid after thrombolysis with tissue plasminogen activator","volume":"17","author":"French","year":"2012","journal-title":"Neurocrit Care"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0325","unstructured":"Acetylsalicylic acid (Aspirin 300). Summary of product characteristics (SPC), Polish version (2008) as amended (2014). http:\/\/www.urpl.gov.pl\/system\/drugs\/pn\/charakterystyka\/2014-02-13_aspirin300_spc_clean_060214.pdf."},{"article-title":"Aspirin 75mg gastro-resistant tablets","year":"2015","series-title":"The summary of product characteristics, British version 2015","key":"10.1016\/j.pjnns.2015.06.003_bib0330"},{"key":"10.1016\/j.pjnns.2015.06.003_bib0335","unstructured":"Clopidogrelum tabl. a 75mg (Clopidix 75 mg). Summary of product characteristics (SPC), Polish version (2004) as amended. http:\/\/leki.urpl.gov.pl\/files\/Clopidix_75.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0340","unstructured":"Clopidogrel\/acetylsalicylic acid Teva 75mg\/75mg film-coated tablets. The summary of product characteristics. The European version 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR-Product_Information\/human\/002272\/WC500173797.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0345","unstructured":"Efient 5mg film coated tablets. The summary of product characteristics. The Polish version 2013. http:\/\/www.urpl.gov.pl\/system\/article_attachments\/attachments\/5218\/original\/ChPL-Efient-h984plannoteted14tt13.pdf?1387450265."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0350","unstructured":"Efient 5mg film coated tablets. The summary of product characteristics. The European version 2013. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000984\/WC500021971.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0355","unstructured":"Brilique 90mg film coated tablets. The summary of product characteristics. The European version 2014. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/001241\/WC500100494.pdf."},{"key":"10.1016\/j.pjnns.2015.06.003_bib0360","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1538-7836.2006.02245.x","article-title":"Normalization of platelet reactivity in clopidogrel treated subjects","volume":"5","author":"Vilahur","year":"2007","journal-title":"J Thromb Haemost"}],"container-title":["Neurologia i Neurochirurgia Polska"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028384315000948?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028384315000948?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,8]],"date-time":"2019-01-08T05:39:53Z","timestamp":1546925993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028384315000948"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,7]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,7]]}},"alternative-id":["S0028384315000948"],"URL":"https:\/\/doi.org\/10.1016\/j.pjnns.2015.06.003","relation":{},"ISSN":["0028-3843"],"issn-type":[{"type":"print","value":"0028-3843"}],"subject":[],"published":{"date-parts":[[2015,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Reversal of antithrombotic treatment in intracranial hemorrhage \u2013 A review of current strategies and guidelines","name":"articletitle","label":"Article Title"},{"value":"Neurologia i Neurochirurgia Polska","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pjnns.2015.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Polish Neurological Society. Published by Elsevier Sp. z o.o. All rights reserved.","name":"copyright","label":"Copyright"}]}}